{"ATC Code":["S01BA04","S - Sensory organs","S02 - Otologicals","S02B - Corticosteroids","S02BA - Corticosteroids","S02BA03 - Prednisolone","C - Cardiovascular system","C05 - Vasoprotectives","C05A - Agents for treatment of hemorrhoids and anal fissures for topical use","C05AA - Corticosteroids","C05AA04 - Prednisolone","A - Alimentary tract and metabolism","A01 - Stomatological preparations","A01A - Stomatological preparations","A01AC - Corticosteroids for local oral treatment","A01AC04 - Prednisolone","H - Systemic hormonal preparations, excl. sex hormones and insulins","H02 - Corticosteroids for systemic use","H02A - Corticosteroids for systemic use, plain","H02AB - Glucocorticoids","H02AB06 - Prednisolone","D - Dermatologicals","D07 - Corticosteroids, dermatological preparations","D07A - Corticosteroids, plain","D07AA - Corticosteroids, weak (group i)","D07AA03 - Prednisolone","R - Respiratory system","R01 - Nasal preparations","R01A - Decongestants and other nasal preparations for topical use","R01AD - Corticosteroids","R01AD02 - Prednisolone","S - Sensory organs","S03 - Ophthalmological and otological preparations","S03B - Corticosteroids","S03BA - Corticosteroids","S03BA02 - Prednisolone","S - Sensory organs","S01 - Ophthalmologicals","S01C - Antiinflammatory agents and antiinfectives in combination","S01CB - Corticosteroids/antiinfectives/mydriatics in combination","S01CB02 - Prednisolone","A - Alimentary tract and metabolism","A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents","A07E - Intestinal antiinflammatory agents","A07EA - Corticosteroids acting locally","A07EA01 - Prednisolone","S - Sensory organs","S01 - Ophthalmologicals","S01B - Antiinflammatory agents","S01BA - Corticosteroids, plain","S01BA04 - Prednisolone","D - Dermatologicals","D07 - Corticosteroids, dermatological preparations","D07X - Corticosteroids, other combinations","D07XA - Corticosteroids, weak, other combinations","D07XA02 - Prednisolone","QD - Dermatologicals","QD07 - Corticosteroids, dermatological preparations","QD07A - Corticosteroids, plain","QD07AA - Corticosteroids, weak (group i)","QD07AA03 - Prednisolone","QR - Respiratory system","QR01 - Nasal preparations","QR01A - Decongestants and other nasal preparations for topical use","QR01AD - Corticosteroids","QR01AD02 - Prednisolone","QS - Sensory organs","QS01 - Ophthalmologicals","QS01C - Antiinflammatory agents and antiinfectives in combination","QS01CB - Corticosteroids/antiinfectives/mydriatics in combination","QS01CB02 - Prednisolone","QC - Cardiovascular system","QC05 - Vasoprotectives","QC05A - Agents for treatment of hemorrhoids and anal fissures for topical use","QC05AA - Corticosteroids","QC05AA04 - Prednisolone","QS - Sensory organs","QS03 - Ophthalmological and otological preparations","QS03B - Corticosteroids","QS03BA - Corticosteroids","QS03BA02 - Prednisolone","QA - Alimentary tract and metabolism","QA01 - Stomatological preparations","QA01A - Stomatological preparations","QA01AC - Corticosteroids for local oral treatment","QA01AC04 - Prednisolone","QD - Dermatologicals","QD07 - Corticosteroids, dermatological preparations","QD07X - Corticosteroids, other combinations","QD07XA - Corticosteroids, weak, other combinations","QD07XA02 - Prednisolone","QA - Alimentary tract and metabolism","QA07 - Antidiarrheals, intestinal anti-inflammatory/antiinfective agents","QA07E - Intestinal antiinflammatory agents","QA07EA - Corticosteroids acting locally","QA07EA01 - Prednisolone","QH - Systemic hormonal preparations, excl. sex hormones and insulin","QH02 - Corticosteroids for systemic use","QH02A - Corticosteroids for systemic use, plain","QH02AB - Glucocorticoids","QH02AB06 - Prednisolone","QS - Sensory organs","QS01 - Ophthalmologicals","QS01B - Antiinflammatory agents","QS01BA - Corticosteroids, plain","QS01BA04 - Prednisolone","QS - Sensory organs","QS02 - Otologicals","QS02B - Corticosteroids","QS02BA - Corticosteroids","QS02BA03 - Prednisolone","H02AB06; A07EA01; S01BA04"],"Absorption, Distribution and Excretion":"Oral prednisolone reaches a Cmax of 113-1343ng/mL with a Tmax of 1.0-2.6 hours. Oral prednisolone is approximately 70% bioavailable.","Aliases":["Prednisolone","Metacortandralone","Hydroretrocortine","Δcortril","Δ-Cortef","Codelcortone","Prenolone","Sterane","Δhydrocortisone","Cortalone","Δcortenol","Donisolone","Fernisolone","HydroΔlone","Paracortol","Hydeltra","Hydroretrocortin","Decortin H","Meti-Derm","Hydrodeltisone","Precortancyl","Predniliderm","Decaprednil","Δ F","Deltisilone","Dicortol","Estilsona","Hydeltrone","PRDL","Precortilon","Precortisyl","Prednelan","Prednicen","Scherisolon","Sterolone","Prelone","Steran","Ulacort","Δ-stab","Hostacortin H","Ultracorten H","Ultracortene-H","Predne-Dome","CO-Hydeltra","Eazolin D","Di-adreson F","Solone","Fernisolone-P","Δ(1)-Hydrocortisone","Δ(1)-Dehydrocortisol","Δ-Ef-Cortelan","Predniretard","1-Dehydrohydrocortisone","Panafcortelone","Prednisolonum","1,2-Dehydrohydrocortisone","11β,17,21-Trihydroxypregna-1,4-diene-3,20-dione","Δ(1)-Cortisol","Δsolone","Klismacort","Δ(1)-dehydrohydrocortisone","1,4-Pregnadiene-11β,17α,21-triol-3,20-dione","(11β)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione","1,4-Pregnadiene-3,20-dione-11β,17α,21-triol","3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene","Aprednislon","EQUISOLON","Dtxsid9021184","NSC-9120","NSC-9900","Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11β)-","CHEBI:8378","Dtxcid301184","Pregna-1,4-diene-3,20-dione, 11β,17,21-trihydroxy-","NSC9120","Adnisolone","Deltidrosol","Kuhlprednon","Lenisolone","Longiprednil","Predeltilone","Prednicortelone","Scheriproct","Capsoid","Dekotil","Dhasolone","Dilacort","Fisopred","Frisolona","Gupisone","Opredsone","Pevanti","Prenilone","Precortisyl fte","PrednisTab","Δ-Phoricol","DiAdresonF","Lepi-Cortinolo","Dontisolon D","Predni-Coelin","Dacortin H","Δ-Diona","Pred-Clysma","Predni-Helvacort","Prednisolone oral","Meti Derm","Δ-F","Di Adreson F","Linola-H-Fett N","Linola-H N","(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta(a)phenanthren-3-one","Δ1-Hydrocortisone","Δ(1)Hydrocortisone","prednisolone oral solution","Δ1-dehydro-hydrocortisone","Prednisolone anhydrous Micronized","200-021-7","Cortisolone","Δlone","Predonine","Predonin","Cotogesic","Delcortol","Dydeltrone","Erbacort","Erbasona","Lentosone","Paracotol","Rolisone","Cordrol","Prednis","Fernisolone P","Derpo PD","Prednisolona","Dexa-Cortidelt hostacortin H","Ultracortene-hydrogen","11β,17α,21-Trihydroxypregna-1,4-diene-3,20-dione","NSC 9120","K 1557","Δ1-Cortisol","Δ1-Dehydrocortisol","CHEMBL131","Δ1-Dehydrohydrocortisone","Neo-Δ-Cortef","Δ-Stab","Mfcd00003649","component of Ataraxoid","Cotolone","component of K-Predne-Dome","(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one","Supercortisol","Δ(sup 1)-Cortisol","Bubbli-Pred","Δ(sup 1)-Hydrocortisone","Δ(sup 1)-Dehydrocortisol","Smr000718761","CCRIS 980","HSDB 3385","Δ(sup 1)-Dehydrohydrocortisone","Pregna-1,20-dione, 11β,17,21-trihydroxy-","Einecs 200-021-7","Unii-9phq9y1olm","Predisolone Sodium Phosphate","Brn 1354103","prednisolon","Hydrocortisone EP Impurity A","Preflam","Pregna-1,20-dione, 11,17,21-trihydroxy-, (11β)-","Δ-Cortef;","Prednisolone CRS","Cas-50-24-8","Ncgc00094764-01","Prednisolone Powder","Δ-hydrocortisone","1-Dehydrocortisol;","TUA","Prestwick_404","Δ-dehydrocortisol","Δ.1-Cortisol","VETSOLONE","11-β,17,21-Trihydroxypregna-1,4-diene-3,20-dione","T-Pred","1,4-Pregnadien-11-β,17-α,21-triol-3,20-dione","1,4-Pregnadiene-11-β,17-α,21-triol-3,20-dione","1,4-Pregnadiene-3,20-dione-11-β,17-α,21-triol","Prednisolone, \u003e=99%","Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11b)-","Prestwick0_000274","Prestwick1_000274","Prestwick2_000274","Prestwick3_000274","Δ-dehydrohydrocortisone","Prednisone impurity B CRS","Ec 200-021-7","Schembl3233","K-Predne-Dome","Prednisolone anhydrous","BSPBio_000148","(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one","4-08-00-03467","Mls001304083","Mls002154250","Mls002207037","Mls002548883","SPBio_002367","BPBio1_000164","GTPL2866","US10196374, Prednisolone","Schembl11040337","BDBM19190","MSK2225","NSC9900","HMS1568H10","HMS2090J05","HMS2095H10","HMS2230P10","HMS3259E09","HMS3712H10","Prednisone impurity b","NSC 9900","Tox21_111327","Tox21_201673","Tox21_302987","EBC-12796","HY-17463R","Lmst02030179","Msk2225-100a","Msk2225-100m","s1737","Akos015894935","Msk2225-1000a","Tox21_111327_1","AC-1773","CCG-220274","DB00860","FP27131","NC00473","Prednisolone for system suitability CRS","Prednisolone for peak identification CRS","Ncgc00179649-01","Ncgc00179649-02","Ncgc00179649-03","Ncgc00179649-04","Ncgc00179649-06","Ncgc00256577-01","Ncgc00259222-01","(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one","AS-13665","HY-17463","CS-0695025","NS00000394","P0637","Prednisolone Solution in Methanol, 100ug/mL","En300-53017","Prednicarbate impurity a","C07369","D00472","D91990","Hydrocortisone impurity a","Prednisolone Solution in Acetonitrile, 100ug/mL","Prednisolone, VETRANAL(TM), analytical standard","Chloroptic-p s.o.p. component prednisolone","Methylprednisolone impurity k","Prednisolone Solution in Acetonitrile, 1000ug/mL","Sr-01000837502","Sr-01000837502-2","Brd-k98039984-001-03-0","Brd-k98039984-001-06-3","Prednisolone acetate impurity b","11β,17,21-trihydroxy-1,4-pregnadiene-3,20-dione","Prednisolone, British Pharmacopoeia (BP) Assay Standard","Z778141968","(11?)-11,17,21-Trihydroxy-pregna-1,4-diene-3,20-dione","Prednisolone, European Pharmacopoeia (EP) Reference Standard","11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (11β)-","11-β,17-α,21-Trihydroxy-1,4-pregnadiene-3,20-dione","11-β,17-α,21-Trihydroxypregna-1,4-diene-3,20-dione","Prednisolone, United States Pharmacopeia (USP) Reference Standard","Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard","Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard","Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material","(8S,9S,10R,11S,13S,14S,17R)-10,13-dimethyl-11,17-bis(oxidanyl)-17-(2-oxidanylethanoyl)-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one","8056-11-9"],"Biological Half-Life":"Prednisolone has a plasma half life of 2.1-3.5 hours. This half life is shorter in children and longer in those with liver disease.","CAS":"50-24-8","Chemical Classes":"Pharmaceutical","ChemicalClasses":["steroid"],"Chirality":"absolute","Color/Form":"Crystals","Drug Classes":["Breast Feeding","Lactation","Milk, Human","Corticosteroids, Systemic","Corticosteroids, Ophthalmic","Glucocorticoids","Anti-Inflammatory Agents"],"Drug Indication":"Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.","Drug Warnings":"VET: IT OFTEN MAY BE CONTRAINDICATED IN CONGESTIVE HEART FAILURE, DIABETES OR OSTEOPOROSIS. EXCEPT FOR EMERGENCY LIFE SAVING USE, IT SHOULD BE OMITTED IN TUBERCULOSIS, CHRONIC NEPHRITIS, CUSHINGOID SYNDROMES, \u0026 PEPTIC ULCER CASES.","DurationOfAction":"","EliminationHalfLife":"2 – 3.5 hours\u003ca href='#cite_note-3'\u003e\u003csup\u003e[3]\u003c/sup\u003e\u003c/a\u003e\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e\u003ca href='#cite_note-5'\u003e\u003csup\u003e[5]\u003c/sup\u003e\u003c/a\u003e","Esters":[],"European Community (EC) Number":"200-021-7","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":37,"Value":{"StringWithMarkup":[{"String":"9PHQ9Y1OLM"}]}},{"Name":"Active Moiety","ReferenceNumber":37,"Value":{"StringWithMarkup":[{"String":"PREDNISOLONE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":37,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - Corticosteroid"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":37,"Value":{"StringWithMarkup":[{"String":"Mechanisms of Action [MoA] - Corticosteroid Hormone Receptor Agonists"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":37,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-5755","Length":12,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Prednisolone"},{"Extra":"CID-5755","Length":12,"Start":61,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/prednisolone"}],"String":"Prednisolone is a Corticosteroid. The mechanism of action of prednisolone is as a Corticosteroid Hormone Receptor Agonist."}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":117,"Value":{"StringWithMarkup":[{"String":"PREDNISOLONE"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":117,"Value":{"StringWithMarkup":[{"String":"Corticosteroid [EPC]; Corticosteroid Hormone Receptor Agonists [MoA]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":118,"Value":{"StringWithMarkup":[{"String":"PREDNISOLONE ORAL"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":118,"Value":{"StringWithMarkup":[{"String":"Corticosteroid [EPC]; Corticosteroid Hormone Receptor Agonists [MoA]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":119,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-5755","Length":12,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/PREDNISOLONE"}],"String":"PREDNISOLONE ORAL SOLUTION"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":119,"Value":{"StringWithMarkup":[{"String":"Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]"}]}}],"Formating":[],"HMDB ID":"HMDB0014998","HeavyAtomCount":26,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Corticosteroids, Systemic; Corticosteroids, Ophthalmic; Glucocorticoids; Anti-Inflammatory Agents","IUPACName":"(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one","InChI":"InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1","InChIKey":"OIGNJSKKLXVSLS-VWUMJDOOSA-N","Interactions":"Seizures have been observed in patients receiving cyclosporine and high doses of methylprednisolone. /Methylprednisolone","KEGG Entries":[{"Id":"D00472","Interactions":[{"Action":"inhibition","Target":"CYP3A"},{"Action":"induction","Target":"CYP3A"}],"Synonyms":["Prednisolone","Delta-cortef"]},{"Id":"D00472","Interactions":[{"Action":"inhibition","Target":"CYP3A"},{"Action":"induction","Target":"CYP3A"}],"Synonyms":["Prednisolone","Delta-cortef"]}],"MeSH Headers":[{"Id":"M0017460","Link":"https://id.nlm.nih.gov/mesh/M0017460.html","Name":"Prednisolone","Ref":176},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":178},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":214},{"Id":"M0001333","Link":"https://id.nlm.nih.gov/mesh/M0001333.html","Name":"Anti-Inflammatory Agents","Ref":215},{"Id":"M0009322","Link":"https://id.nlm.nih.gov/mesh/M0009322.html","Name":"Glucocorticoids","Ref":216},{"Id":"M0028300","Link":"https://id.nlm.nih.gov/mesh/M0028300.html","Name":"Antineoplastic Agents, Hormonal","Ref":217}],"MeSH Pharmacological Classification":[{"Id":"M0001333","Link":"https://id.nlm.nih.gov/mesh/M0001333.html","Name":"Anti-Inflammatory Agent","Ref":215},{"Id":"M0009322","Link":"https://id.nlm.nih.gov/mesh/M0009322.html","Name":"Glucocorticoid","Ref":216},{"Id":"M0028300","Link":"https://id.nlm.nih.gov/mesh/M0028300.html","Name":"Antineoplastic Agents, Hormonal","Ref":217}],"Mechanism of Action":"The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.  Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.  Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.","Melting Point":"235 °C","Metabolism/Metabolites":"Prednisolone can be reversibly metabolized to [prednisone] which is then metabolized to 17α,21-dihydroxy-pregnan-1,4,6-trien-3,11,30-trione (M-XVII), 20α-dihydro-prednisone (M-V), 6βhydroxy-prednisone (M-XII), 6α-hydroxy-prednisone (M-XIII), or 20β-dihydro-prednisone (M-IV). 20β-dihydro-prednisone is metabolized to 17α,20ξ,21-trihydroxy-5ξ-pregn-1-en-3,11-dione(M-XVIII). Prednisolone is metabolized to Δ6-prednisolone (M-XI), 20α-dihydro-prednisolone (M-III), 20β-dihydro-prednisolone (M-II), 6αhydroxy-prednisolone (M-VII), or 6βhydroxy-prednisolone(M-VI). 6αhydroxy-prednisolone is metabolized to 6α,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-X). 6βhydroxy-prednisolone is metabolized to 6β,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-VIII), 6β,11β,17α,20α,21-pentahydroxypregnan-1,4-diene-3-one (M-IX), and 6β,11β,17α,21-tetrahydroxy-5ξ-pregn-1-en-3,20-dione (M-XIV). MVIII is metabolized to 6β,11β,17α,20β,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XV) and then to MXIV, while MIX is metabolized to 6β,11β,17α,20α,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XVI) and then to MXIV. These metabolites and their glucuronide conjugates are excreted predominantly in the urine.","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e28\u003c/sub\u003eO\u003csub\u003e5\u003c/sub\u003e","MolecularWeight":"360.4 g/mol","Non-Human Toxicity Values":"LD50 Mouse ip \u003e 1000 mg/kg body weight /Prednisolone acetate/","Odor":"Odorless","Opticalactivity":"UNSPECIFIED","Pharmacodynamics":"Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Prednisolone has a short duration of action as the half life is 2.1-3.5 hours. Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.","Physical Description":"Solid","PubChemId":5755,"Record Description":["LiverTox|Endocrine|Immune suppression|Corticosteroid"],"Records":{"UNII":{"Impurities":["(11β,20s)-11,17,20,21-tetrahydroxypregna-1,4-dien-3-one",".delta.'-dehydrocortexolone","prednisolone acetate","11.beta.,14.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione","hydrocortisone","prednisone","(11.alpha.)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione",".delta.6-prednisolone","6.beta.-hydroxyprednisolone","(11.beta.)-11,21-dihydroxypregna-1,4-diene-3,20-dione"]}},"RefChem":"6161","RefCount":6,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Prednisolone","Name":"Prednisolone","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q11426176","Name":"Prednisolone","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB00860","Name":"Prednisolone","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5755","Name":"Prednisolone","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=50-24-8","Name":"Prednisolone","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014998","Name":"Prednisolone","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07369","Name":"Prednisolone","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/9PHQ9Y1OLM","Name":"Prednisolone","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9021184","Name":"Prednisolone","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5755, Prednisolone. Accessed April 24, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5755\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5755\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Prednisolone. UNII: 9PHQ9Y1OLM. Global Substance Registration System. Accessed April 24, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9PHQ9Y1OLM\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/9PHQ9Y1OLM\u003c/a\u003e","Pickup ME. Clinical pharmacokinetics of prednisone and prednisolone. Clinical Pharmacokinetics. 1979; 4(2):111–128.","Bergrem H, Grøttum P, Rugstad HE. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. European Journal of Clinical Pharmacology. 1983; 24(3):415–419.","Bashar T, Apu MN, Mostaid MS, Islam MS, Hasnat A. Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers. Dose-Response. 2018; 16(3)"],"SMILES":"C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O","SaltData":[],"Salts":[],"Scheduling":[{"gov":"United Kingdom","ref":[],"schedule":"prescription only substance"},{"gov":"United States","ref":[],"schedule":"prescription only substance"}],"Solubility":"SPECIFIC OPTICAL ROTATION: +102.5 DEG @ 25 °C/D; PH OF 1% SOLN 7.5 TO 8.5; SOL IN WATER, METHANOL, ETHANOL. /PHOSPHATE SODIUM/","StereoisomerData":[],"Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 125.699 87.038\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h126v88H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m83.653 23.078-1.597 15.157M82.056 38.235l-13.208-7.62M68.848 30.615l-13.208 7.62M55.64 38.235v15.24M55.64 53.475l13.208 7.62M68.848 61.095l13.208-7.62M82.056 38.235v15.24M82.056 53.475l14.427 4.775M96.483 58.25l9.043-12.395M105.526 45.855l-9.043-12.294M82.056 38.235l14.427-4.674M96.483 33.561l13.171-7.668\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m109.649 24.486 10.547 6.038M108.437 26.602l10.547 6.038\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m120.196 30.524-5.274-3.019M118.984 32.64l-5.274-3.019\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m109.654 25.893-.055-15.24M109.599 10.653 99.655 4.96M96.483 33.561l-2.734-10.903M68.848 61.095v15.24M68.848 76.335l-13.208 7.62M55.64 83.955l-13.208-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m29.224 83.955 13.208-7.62M29.224 81.139l10.77-6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m29.224 83.955-13.208-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M17.236 77.038 6.707 83.119M16.016 74.927 5.487 81.008\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m6.707 83.119 5.265-3.041M5.487 81.008l5.265-3.04\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"M16.016 76.335v-15.24\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m29.224 53.475-13.208 7.62M29.224 56.29l-10.769 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m29.224 53.475 13.208 7.62M55.64 53.475l-13.208 7.62M42.432 76.335v-15.24M42.432 61.095v-15.24M55.64 38.235l-3.845-10.573M55.64 38.235l-11.967-.002M55.64 53.475l-14.326-8.293M68.848 61.095l-1.966-11.181M82.056 53.475l1.157 11.318\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M125.139 33.463q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.245-.571-.245-1.333 0-.75.245-1.31.25-.566.756-.881t1.274-.316q.732 0 1.232.316.5.309.756.875t.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M98.632 3.078q0 .756-.255 1.328-.256.565-.757.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881T96.388.56q.732 0 1.232.316.501.309.757.875.255.565.255 1.327m-3.863 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452M93.552 5.531h-.619V3.245h-2.512v2.286h-.613v-4.9h.613v2.072h2.512V.631h.619z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M95.036 18.776q0 .756-.256 1.327-.256.566-.756.881-.501.316-1.245.316-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.233.315.5.31.756.875.256.566.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M89.955 21.228h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"none\" d=\"M5.078 83.954q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M52.69 23.91q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.566.756-.881t1.274-.316q.732 0 1.232.316.5.309.756.875t.256 1.328m-3.863 0q0 .922.386 1.458.393.53 1.221.53.839 0 1.22-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.208-.524-.834 0-1.227.524-.392.524-.392 1.453M47.61 26.362h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.071h2.512v-2.071h.619z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M42.272 40.683h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619zM40.102 45.846h-.619V43.56h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619zM68.081 48.535h-.619v-2.286H64.95v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619zM85.478 71.085h-.62v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.62z\" class=\"atom\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m83.653 23.078-.798 7.579M99.655 4.96l4.972 2.846M99.655 4.96l4.972 2.846M93.749 22.658l1.367 5.452M93.749 22.658l1.367 5.452M51.795 27.662l1.923 5.286M51.795 27.662l1.923 5.286\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Therapeutic Uses":"Anti-Inflammatory Agents, Steroidal; Antineoplastic Agents, Hormonal; Glucocorticoids, Synthetic","Title":"Prednisolone","UNII":"9PHQ9Y1OLM","Wikidata":"Q11426176","Wikipedia":"Prednisolone","XLogP":1.6}